NASDAQ:ALLR Allarity Therapeutics Q3 2025 Earnings Report $1.43 0.00 (0.00%) Closing price 03:59 PM EasternExtended Trading$1.46 +0.03 (+2.38%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Allarity Therapeutics EPS ResultsActual EPS-$0.19Consensus EPS -$0.23Beat/MissBeat by +$0.04One Year Ago EPSN/AAllarity Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAllarity Therapeutics Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Allarity Therapeutics Earnings HeadlinesAllarity Therapeutics, Inc.: Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing CampaignAugust 15, 2026 | finanznachrichten.deAllarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing CampaignAugust 14, 2026 | globenewswire.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.August 20 at 1:00 AM | Awesomely (Ad)Allarity Therapeutics (ALLR) Projected to Release Earnings on FridayAugust 14, 2026 | americanbankingnews.comAllarity Therapeutics Inc.August 12, 2026 | marketwatch.comAllarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA RegistrationJuly 7, 2026 | globenewswire.comSee More Allarity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Allarity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Allarity Therapeutics and other key companies, straight to your email. Email Address About Allarity TherapeuticsAllarity Therapeutics (NASDAQ:ALLR) A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval. The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials. These programs explore combinations of targeted therapy and standard chemotherapy in colorectal, ovarian and breast cancers. Allarity’s diagnostic platform supports these efforts by employing gene expression signatures to match treatments with tumor biology, offering a more personalized approach than conventional “one‐size‐fits‐all” regimens. Founded in 2015 as OncoBay, the company rebranded to Allarity Therapeutics in 2020 to reflect its expanded precision medicine strategy. Headquartered in Copenhagen, Denmark, Allarity maintains a U.S. presence in Cambridge, Massachusetts, to facilitate clinical collaborations and regulatory interactions. Under the leadership of CEO Christian M. Vedelsdal and an experienced executive team, the company has built partnerships with research institutions and contract organizations to advance its clinical programs. Allarity serves global markets by enrolling patients across North America and Europe in its ongoing trials. The company’s outward focus on combining diagnostics with therapeutics aligns with an evolving industry trend toward more targeted and data‐driven drug development, positioning Allarity to address significant unmet needs in oncology with a precision‐guided approach.View Allarity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Walmart's Post-Earnings Drop Could Be a Buying Opportunity3 Energy Stocks Raising Dividends as the Sector Surges5 Reasons the S&P 500 Could Keep Rallying Through Year-EndSociedad Química y Minera’s Lithium Boom Is Back, But Iodine Steals the ShowNasdaq’s 23-Hour Trading Push Could Turn Global Liquidity Into a Growth EngineForget Chips: These 3 Stocks Are Building the AI Data Center BoomAnalog Devices’ AI Pivot Could Push Shares to Fresh Highs Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
